Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L01Orphan Medicine

Flynpovi(eflornithine hydrochloride;sulindac)

Adenomatous Polyposis Coli

Marketing Authorisation Holder: Cancer Prevention Pharma (Ireland) Limited

INN: eflornithine;sulindac

Indication

Treatment of adults patients with familial adenomatous polyposis (FAP)

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Flynpovi — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.